Use of tg02 for treating gliomas in pediatric subjects
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, Adastra Pharmaceuticals, Inc.
InventorsSameer AGNIHOTRI, Alberto BRONISCER, Ian F. POLLACK, Thomas M. ESTOK
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.
Claims20
A method for treating diffuse intrinsic pontine glioma (DIPG) in a pediatric human subject, comprising administering to the subject a therapeutically effective amount of (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]-heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (TG02), or a pharmaceutically acceptable salt thereof, in combination with radiation therapy.
A kit for treating diffuse intrinsic pontine glioma (DIPG) in a pediatric human subject, comprising (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]-heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (TG02), or a pharmaceutically acceptable salt thereof, and instructions for administering TG02 in combination with radiation therapy.
Dependencies are inferred from the claim text.